Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 366

1.

Flexible linkers in CaMKII control the balance between activating and inhibitory autophosphorylation.

Bhattacharyya M, Lee YK, Muratcioglu S, Qiu B, Nyayapati P, Schulman H, Groves JT, Kuriyan J.

Elife. 2020 Mar 9;9. pii: e53670. doi: 10.7554/eLife.53670.

2.

Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.

Schulman H, Niward K, Abate E, Idh J, Axenram P, Bornefall A, Forsgren S, Jakobsson J, Öhrling C, Kron M, Brudin L, Diro E, Getachew Kebede A, Paues J, Bruchfeld J, Wejse C, Stendahl O, Schön T.

Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1155-1161. doi: 10.5588/ijtld.18.0634.

PMID:
31718751
3.

CaM Kinase: Still Inspiring at 40.

Bayer KU, Schulman H.

Neuron. 2019 Aug 7;103(3):380-394. doi: 10.1016/j.neuron.2019.05.033. Review.

PMID:
31394063
4.

Conformational coupling by trans-phosphorylation in calcium calmodulin dependent kinase II.

Pandini A, Schulman H, Khan S.

PLoS Comput Biol. 2019 May 31;15(5):e1006796. doi: 10.1371/journal.pcbi.1006796. eCollection 2019 May.

5.

The intellectual disability-associated CAMK2G p.Arg292Pro mutation acts as a pathogenic gain-of-function.

Proietti Onori M, Koopal B, Everman DB, Worthington JD, Jones JR, Ploeg MA, Mientjes E, van Bon BW, Kleefstra T, Schulman H, Kushner SA, Küry S, Elgersma Y, van Woerden GM.

Hum Mutat. 2018 Dec;39(12):2008-2024. doi: 10.1002/humu.23647. Epub 2018 Sep 19.

6.

Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor.

Neef S, Steffens A, Pellicena P, Mustroph J, Lebek S, Ort KR, Schulman H, Maier LS.

J Mol Cell Cardiol. 2018 Feb;115:73-81. doi: 10.1016/j.yjmcc.2017.12.015. Epub 2017 Dec 30.

7.

Molecular mechanism of activation-triggered subunit exchange in Ca(2+)/calmodulin-dependent protein kinase II.

Bhattacharyya M, Stratton MM, Going CC, McSpadden ED, Huang Y, Susa AC, Elleman A, Cao YM, Pappireddi N, Burkhardt P, Gee CL, Barros T, Schulman H, Williams ER, Kuriyan J.

Elife. 2016 Mar 7;5. pii: e13405. doi: 10.7554/eLife.13405.

8.

CaMKII inhibitors: from research tools to therapeutic agents.

Pellicena P, Schulman H.

Front Pharmacol. 2014 Feb 20;5:21. doi: 10.3389/fphar.2014.00021. eCollection 2014. Review.

9.

Correction: Activation-triggered subunit exchange between CaMKII holoenzymes facilitates the spread of kinase activity.

Stratton M, Lee IH, Bhattacharyya M, Christensen SM, Chao LH, Schulman H, Groves JT, Kuriyan J.

Elife. 2014 Feb 11;3:e02490. doi: 10.7554/eLife.02490. No abstract available.

10.

Activation-triggered subunit exchange between CaMKII holoenzymes facilitates the spread of kinase activity.

Stratton M, Lee IH, Bhattacharyya M, Christensen SM, Chao LH, Schulman H, Groves JT, Kuriyan J.

Elife. 2014 Jan 28;3:e01610. doi: 10.7554/eLife.01610. Erratum in: Elife. 2014;3:e02490.

11.

Structural studies on the regulation of Ca2+/calmodulin dependent protein kinase II.

Stratton MM, Chao LH, Schulman H, Kuriyan J.

Curr Opin Struct Biol. 2013 Apr;23(2):292-301. doi: 10.1016/j.sbi.2013.04.002. Epub 2013 Apr 27. Review.

12.

8OHdG is not a biomarker for Huntington disease state or progression.

Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, Becker C, Sampaio C, Tobin AJ, Schulman H.

Neurology. 2013 May 21;80(21):1934-41. doi: 10.1212/WNL.0b013e318293e1a1. Epub 2013 Apr 24.

13.

Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis.

Dhaunchak AS, Becker C, Schulman H, De Faria O Jr, Rajasekharan S, Banwell B, Colman DR, Bar-Or A; Canadian Pediatric Demyelinating Disease Group.

Ann Neurol. 2012 May;71(5):601-13. doi: 10.1002/ana.22693. Epub 2012 Apr 4.

PMID:
22473675
14.

Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.

Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI.

Arch Neurol. 2012 Jan;69(1):96-104. doi: 10.1001/archneurol.2011.642.

15.

A mechanism for tunable autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II holoenzyme.

Chao LH, Stratton MM, Lee IH, Rosenberg OS, Levitz J, Mandell DJ, Kortemme T, Groves JT, Schulman H, Kuriyan J.

Cell. 2011 Sep 2;146(5):732-45. doi: 10.1016/j.cell.2011.07.038. Erratum in: Cell. 2011 Oct 28;147(3):704.

16.

Protein standard absolute quantification (PSAQ) method for the measurement of cellular ubiquitin pools.

Kaiser SE, Riley BE, Shaler TA, Trevino RS, Becker CH, Schulman H, Kopito RR.

Nat Methods. 2011 Jul 10;8(8):691-6. doi: 10.1038/nmeth.1649.

17.

In search of cellular immunophenotypes in the blood of children with autism.

Ashwood P, Corbett BA, Kantor A, Schulman H, Van de Water J, Amaral DG.

PLoS One. 2011 May 4;6(5):e19299. doi: 10.1371/journal.pone.0019299.

18.

Ca/Calmodulin-dependent Protein Kinase II in Heart Failure.

Schulman H, Anderson ME.

Drug Discov Today Dis Mech. 2010 Summer;7(2):e117-e122. No abstract available.

19.

Deconvoluting post-transplant immunity: cell subset-specific mapping reveals pathways for activation and expansion of memory T, monocytes and B cells.

Grigoryev YA, Kurian SM, Avnur Z, Borie D, Deng J, Campbell D, Sung J, Nikolcheva T, Quinn A, Schulman H, Peng SL, Schaffer R, Fisher J, Mondala T, Head S, Flechner SM, Kantor AB, Marsh C, Salomon DR.

PLoS One. 2010 Oct 14;5(10):e13358. doi: 10.1371/journal.pone.0013358.

20.

Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation.

Chao LH, Pellicena P, Deindl S, Barclay LA, Schulman H, Kuriyan J.

Nat Struct Mol Biol. 2010 Mar;17(3):264-72. doi: 10.1038/nsmb.1751. Epub 2010 Feb 7.

21.

Protein biomarker identification in the CSF of patients with CNS lymphoma.

Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL.

J Clin Oncol. 2008 Jan 1;26(1):96-105. Epub 2007 Dec 3.

22.

Global changes to the ubiquitin system in Huntington's disease.

Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR.

Nature. 2007 Aug 9;448(7154):704-8.

PMID:
17687326
23.

[Cellular mechanisms of protein quality control].

Bennett EJ, Shaler T, Gonzalez-Zulueta M, Schulman HF, Iwata A, Riley BE, Johnston JA, Bucci M, Nukina N, Ellerby L, Kopito RR.

Rinsho Shinkeigaku. 2006 Nov;46(11):805. Japanese. No abstract available.

PMID:
17432184
24.
25.

A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins.

Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, Ashwood P, Rocke DM, Sharp FR.

Mol Psychiatry. 2007 Mar;12(3):292-306. Epub 2006 Dec 26.

PMID:
17189958
26.

Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease.

Anderson ME, Higgins LS, Schulman H.

Nat Clin Pract Cardiovasc Med. 2006 Aug;3(8):437-45. Review.

PMID:
16874356
27.

Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B.

Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P.

J Neurosci. 2006 Jan 25;26(4):1164-74.

28.

CaMKII structure--an elegant design.

Hunter T, Schulman H.

Cell. 2005 Dec 2;123(5):765-7.

29.

CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation.

Hudmon A, Schulman H, Kim J, Maltez JM, Tsien RW, Pitt GS.

J Cell Biol. 2005 Nov 7;171(3):537-47.

30.

A mechanism for Ca2+/calmodulin-dependent protein kinase II clustering at synaptic and nonsynaptic sites based on self-association.

Hudmon A, Lebel E, Roy H, Sik A, Schulman H, Waxham MN, De Koninck P.

J Neurosci. 2005 Jul 27;25(30):6971-83.

31.

Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis.

Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C.

Exp Cell Res. 2005 Mar 10;304(1):244-55. Epub 2004 Nov 26.

PMID:
15707589
32.
33.

Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo.

Chiba T, Hashimoto Y, Tajima H, Yamada M, Kato R, Niikura T, Terashita K, Schulman H, Aiso S, Kita Y, Matsuoka M, Nishimoto I.

J Neurosci Res. 2004 Nov 15;78(4):542-52.

PMID:
15478191
34.

Promiscuous protein biotinylation by Escherichia coli biotin protein ligase.

Choi-Rhee E, Schulman H, Cronan JE.

Protein Sci. 2004 Nov;13(11):3043-50. Epub 2004 Sep 30.

35.

Activity-dependent regulation of calcium/calmodulin-dependent protein kinase II localization.

Schulman H.

J Neurosci. 2004 Sep 29;24(39):8399-403. Review. No abstract available.

36.

An ultrasensitive Ca2+/calmodulin-dependent protein kinase II-protein phosphatase 1 switch facilitates specificity in postsynaptic calcium signaling.

Bradshaw JM, Kubota Y, Meyer T, Schulman H.

Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10512-7. Epub 2003 Aug 19.

37.

Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII.

Fink CC, Bayer KU, Myers JW, Ferrell JE Jr, Schulman H, Meyer T.

Neuron. 2003 Jul 17;39(2):283-97.

38.

Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin.

Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, Schulman H, Hell JW.

J Biol Chem. 2002 Dec 13;277(50):48441-8. Epub 2002 Oct 13.

39.
40.

Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function.

Hudmon A, Schulman H.

Annu Rev Biochem. 2002;71:473-510. Epub 2001 Nov 9. Review.

PMID:
12045104
41.

The molecular basis of CaMKII function in synaptic and behavioural memory.

Lisman J, Schulman H, Cline H.

Nat Rev Neurosci. 2002 Mar;3(3):175-90. Review.

PMID:
11994750
42.

Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II.

Hudmon A, Schulman H.

Biochem J. 2002 Jun 15;364(Pt 3):593-611. Review.

43.
44.

Upper airway obstruction-related sleep apnea in a child with thalassemia intermedia.

Kapelushnik J, Shalev H, Schulman H, Moser A, Tamary H.

J Pediatr Hematol Oncol. 2001 Nov;23(8):525-6.

PMID:
11878781
45.

Massive cavitation of solid pulmonary metastatic lesions in a breast cancer patient: a case report.

Mermershtain W, Schulman H, Hertzanu Y, Cohen Y.

Ann Oncol. 2002 Jan;13(1):173-4.

46.

Solution and chip arrays in protein profiling.

Zhou H, Roy S, Schulman H, Natan MJ.

Trends Biotechnol. 2001 Oct;19(10 Suppl):S34-9. Review.

PMID:
11780969
47.

Regulation of signal transduction by protein targeting: the case for CaMKII.

Bayer KU, Schulman H.

Biochem Biophys Res Commun. 2001 Dec 21;289(5):917-23. Review.

PMID:
11741277
48.

Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis.

Fladmark KE, Brustugun OT, Mellgren G, Krakstad C, Boe R, Vintermyr OK, Schulman H, Doskeland SO.

J Biol Chem. 2002 Jan 25;277(4):2804-11. Epub 2001 Nov 16.

49.

Kinetic and pharmacological properties of GABA(A) receptors in single thalamic neurons and GABA(A) subunit expression.

Browne SH, Kang J, Akk G, Chiang LW, Schulman H, Huguenard JR, Prince DA.

J Neurophysiol. 2001 Nov;86(5):2312-22.

50.

The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity.

Zhang T, Johnson EN, Gu Y, Morissette MR, Sah VP, Gigena MS, Belke DD, Dillmann WH, Rogers TB, Schulman H, Ross J Jr, Brown JH.

J Biol Chem. 2002 Jan 11;277(2):1261-7. Epub 2001 Nov 2.

Supplemental Content

Loading ...
Support Center